Par Files Declaratory Suit Over Diabetes Generic

Law360, New York (April 16, 2009, 12:00 AM EDT) -- Novartis AG and Japanese drugmaker Ajinomoto Co. Inc. have been hit with a declaratory action by Par Pharmaceutical Inc., which is looking to market a generic version of the companies’ type 2 diabetes drug Starlix.

Par filed the complaint Wednesday in the U.S. District Court for the Eastern District of Pennsylvania, asking for a declaratory judgment that it will not infringe the six patents owned by Novartis and Ajinomoto related to Starlix.

Novartis currently holds a new drug application for 60 mg and 120 mg oral...
To view the full article, register now.